Literature DB >> 19273410

The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.

Reanne Booker1, Karin Olson, Linda M Pilarski, Joseph P Noon, Nizar J Bahlis.   

Abstract

PURPOSE/
OBJECTIVES: To investigate the relationships among physiologic variables, fatigue, and quality of life (QOL) in patients with multiple myeloma.
DESIGN: Cross-sectional, descriptive, exploratory.
SETTING: Outpatient ambulatory care clinics at a tertiary oncology center. SAMPLE: 56 patients with multiple myeloma were accrued consecutively via nonprobability sampling strategy.
METHODS: Study participants completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and the Functional Assessment of Cancer Therapy-Fatigue. Physiologic variables and demographic data were collected from patient charts. MAIN RESEARCH VARIABLES: Hemoglobin (hgb), C-reactive protein (CRP), fatigue, and QOL.
FINDINGS: Statistically significant correlations were found among hgb and two measures of fatigue and QOL, as well as among CRP and two measures of fatigue and QOL. Regression analysis revealed that as soon as the effect of CRP was removed, hgb was no longer a significant predictor of fatigue or QOL.
CONCLUSIONS: Although significant relationships between hgb and fatigue and hgb and QOL were identified, CRP made a significant contribution to predicting the variance in fatigue and QOL, whereas hgb did not. The findings suggest that higher CRP is predictive of greater fatigue and lower QOL. IMPLICATIONS FOR NURSING: Nurses play an integral role in the assessment and management of cancer-related fatigue. Greater understanding of the pathophysiology of fatigue may lead to progress in assessment and intervention, with the ultimate goal of reducing cancer-related fatigue and improving QOL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273410     DOI: 10.1188/09.ONF.209-216

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  7 in total

Review 1.  A systematic review of the association between immunogenomic markers and cancer-related fatigue.

Authors:  L N Saligan; H S Kim
Journal:  Brain Behav Immun       Date:  2012-05-14       Impact factor: 7.217

Review 2.  The biology of cancer-related fatigue: a review of the literature.

Authors:  Leorey N Saligan; Karin Olson; Kristin Filler; David Larkin; Fiona Cramp; Sriram Yennurajalingam; Yennu Sriram; Carmen P Escalante; Auro del Giglio; Kord M Kober; Jayesh Kamath; Oxana Palesh; Karen Mustian
Journal:  Support Care Cancer       Date:  2015-05-15       Impact factor: 3.603

3.  Transitoriness in cancer patients: a cross-sectional survey of lung and gastrointestinal cancer patients.

Authors:  Maya Shaha; Vinciya Pandian; Michael A Choti; Eden Stotsky; Joseph M Herman; Yasmin Khan; Carol Libonati; Timothy M Pawlik; Richard D Schulick; Anne E Belcher
Journal:  Support Care Cancer       Date:  2010-02-21       Impact factor: 3.603

4.  AT2 receptor: Its role in obesity associated hypertension.

Authors:  Quaisar Ali; Tahir Hussain
Journal:  Int J Clin Pharmacol Toxicol       Date:  2012-10-16

5.  Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.

Authors:  R Baz; H M Lin; A-M Hui; R D Harvey; K Colson; K Gallop; P Swinburn; J Laubach; D Berg; P Richardson
Journal:  Support Care Cancer       Date:  2015-02-24       Impact factor: 3.603

6.  Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation.

Authors:  A Khalafallah; K McDonnell; H U Dawar; I Robertson; D Woods
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

7.  Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Authors:  David Cella; Jan McKendrick; Amber Kudlac; Antonio Palumbo; Abderrahim Oukessou; Ravi Vij; Teresa Zyczynski; Catherine Davis
Journal:  Ann Hematol       Date:  2018-09-04       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.